PuREC

PuREC is a clinical-stage biotechnology company based in Japan that focuses on regenerative medicine through the use of ultra-pure mesenchymal stem cells (MSCs). The company utilizes its proprietary "Rapidly Expanding Cells" (REC) technology to isolate a specific, high-potency subpopulation of MSCs characterized by the expression of specific surface markers. These REC cells demonstrate significantly higher proliferative capacity and more consistent differentiation potential than standard MSCs, addressing the common issue of heterogeneity in cell therapies. PuREC is currently advancing its lead program for the treatment of hypophosphatasia into clinical trials, while also developing a pipeline for indications such as osteoarthritis and spinal cord injury. By providing a standardized and highly purified cell source, the company seeks to improve the efficacy and reliability of regenerative treatments.